Regenerative Medicine, Cell Therapy, Small Molecule

Regen BioPharma is a biotechnology company dedicated to advancing innovative treatments for cancer and autoimmune diseases through a variety of cutting-edge technologies. The company focuses on autologous cell therapies, RNA and DNA-based immunotherapies, and small molecules. A significant aspect of their research involves modulating the immune checkpoint NR2F6, which plays a crucial role in regulating T cell function. Regen BioPharma is developing a range of therapies, including CAR-T cells that are genetically modified to block NR2F6, as well as small molecule drugs designed to activate or inhibit this immune checkpoint. Their product pipeline also includes dendritic cell-based immunotherapies, such as dCellVax and tCellVax, which utilize gene silencing to stimulate the immune system.

In addition to their focus on NR2F6, Regen BioPharma is exploring various other technologies, including the KimerApt platform, which employs aptamers—short DNA or RNA sequences that can bind to and inhibit specific receptors, similar to antibodies. The DuraCAR technology aims to enhance the durability of CAR-T cells by inhibiting NR2F6 expression through shRNA. Furthermore, the company is developing HemaXellerate, a treatment designed to repair damaged bone marrow in patients suffering from conditions like aplastic anemia and those undergoing chemotherapy or radiotherapy. All of these technologies are protected by a robust portfolio of patents, underscoring the company's commitment to innovation in the field of immune-oncology and autoimmune therapies.

United States

Regen BioPharma Inc. is a publicly traded biotechnology company focused on developing innovative treatments using autologous cell therapies, RNA and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmune disease space.

Regen BioPharma

Company Details